Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma

NCT05037669 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No available investigational product

Conditions

Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Non Hodgkin Lymphoma

Interventions

BIOLOGICAL: PACE CART19

Sponsor

University of Pennsylvania